Ugwumba Chidozie, identified as a ten percent owner of Clene Inc. (NASDAQ:CLNN), reported the sale of 4,278 shares of common stock on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were disposed of at $4.97 per share, producing total proceeds of $21,261. After the disposition, Chidozie directly holds 426,816 shares through SymBiosis II, LLC, per the filing.
The insider sale occurred as the stock showed near-term turbulence. InvestingPro data cited in the filing notes shares had fallen roughly 10% over the prior week. At the time of the filing, Clene's shares were trading at $4.89 and the company carried a market capitalization of $58.07 million. InvestingPro analysis also indicates the stock appears undervalued based on its Fair Value assessment.
Beyond the insider transaction, Clene disclosed financing and regulatory developments tied to its investigational treatment for amyotrophic lateral sclerosis (ALS), CNM-Au8.
The company announced a registered direct offering totaling in excess of $28 million intended to support CNM-Au8. Investors participating in the financing include Boxer Capital, Coastlands Capital, Vivo Capital, and current insider investors. An initial tranche of more than $6 million is expected to fund operations into the third quarter of 2026 and could cover the period during which the U.S. Food and Drug Administration considers the company's New Drug Application acceptance decision.
In parallel, Clene has been granted an in-person Type C meeting with the FDA to discuss biomarker data related to its investigational ALS treatment. The planned discussion will focus on new analyses that show modest reductions in neurofilament light chain levels are associated with lower mortality risk in ALS patients. The company said these findings could support neurofilament light chain reduction as a surrogate endpoint for accelerated approval.
These items - the insider sale, the recent market volatility and valuation signal, the committed financing, and the FDA engagement on biomarker data - together outline the immediate developments shaping Clene's timetable for CNM-Au8 and the company's near-term capital needs.